Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections

Clara Inkyung Lee, Howard Gurney

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The role of the selective oestrogen receptor modulator, tamoxifen, is well established in the treatment of hormone sensitive breast cancer. The metabolism of tamoxifen to its active metabolites is however complex. Despite much research, a conclusive stance on the clinical implications of CYP2D6, active metabolites including endoxifen in efficacy and toxicity, is yet to be reached. Herein we examine the literature to clarify the connections between tamoxifen, CYP2D6 and endoxifen with resultant clinical recommendations.

LanguageEnglish
Pages4-10
Number of pages7
JournalCancer Forum
Volume40
Issue number3
Publication statusPublished - 1 Nov 2016

Fingerprint

Cytochrome P-450 CYP2D6
Tamoxifen
Hormones
Breast Neoplasms
Selective Estrogen Receptor Modulators
Research
4-hydroxy-N-desmethyltamoxifen

Cite this

@article{f9e4443a446e45828e01bd89942f76d1,
title = "Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections",
abstract = "The role of the selective oestrogen receptor modulator, tamoxifen, is well established in the treatment of hormone sensitive breast cancer. The metabolism of tamoxifen to its active metabolites is however complex. Despite much research, a conclusive stance on the clinical implications of CYP2D6, active metabolites including endoxifen in efficacy and toxicity, is yet to be reached. Herein we examine the literature to clarify the connections between tamoxifen, CYP2D6 and endoxifen with resultant clinical recommendations.",
author = "Lee, {Clara Inkyung} and Howard Gurney",
year = "2016",
month = "11",
day = "1",
language = "English",
volume = "40",
pages = "4--10",
journal = "Cancer Forum",
issn = "0311-306X",
publisher = "Cancer Council Australia",
number = "3",

}

Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer : demystifying the connections. / Lee, Clara Inkyung; Gurney, Howard.

In: Cancer Forum, Vol. 40, No. 3, 01.11.2016, p. 4-10.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer

T2 - Cancer Forum

AU - Lee, Clara Inkyung

AU - Gurney, Howard

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The role of the selective oestrogen receptor modulator, tamoxifen, is well established in the treatment of hormone sensitive breast cancer. The metabolism of tamoxifen to its active metabolites is however complex. Despite much research, a conclusive stance on the clinical implications of CYP2D6, active metabolites including endoxifen in efficacy and toxicity, is yet to be reached. Herein we examine the literature to clarify the connections between tamoxifen, CYP2D6 and endoxifen with resultant clinical recommendations.

AB - The role of the selective oestrogen receptor modulator, tamoxifen, is well established in the treatment of hormone sensitive breast cancer. The metabolism of tamoxifen to its active metabolites is however complex. Despite much research, a conclusive stance on the clinical implications of CYP2D6, active metabolites including endoxifen in efficacy and toxicity, is yet to be reached. Herein we examine the literature to clarify the connections between tamoxifen, CYP2D6 and endoxifen with resultant clinical recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85017634246&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 4

EP - 10

JO - Cancer Forum

JF - Cancer Forum

SN - 0311-306X

IS - 3

ER -